Evidence map›Paper›PMID 29508243›Full record

SynthesisCNS drugs2018

Adjunctive Eslicarbazepine Acetate in Pediatric Patients with Focal Epilepsy: A Systematic Review and Meta-Analysis.

Simona Lattanzi, Francesco Brigo, Elisabetta Grillo, Claudia Cagnetti, Alberto Verrotti, Gaetano Zaccara, Mauro Silvestrini

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in CNS drugs, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 5 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 5 syntheses or guidelines pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Article
  8. Journal of pediatric genetics · 2020
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Simona LattanziNeurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Via Conca 71, Ancona, 60020, Italy. alfierelattanzisimona@gmail.com.
Francesco BrigoDepartment of Neuroscience, Biomedicine and Movement Science, University of Verona, Verona, Italy.
Elisabetta GrilloMedical Department Eisai s.r.l., San Donato Milanese, Italy.
Claudia CagnettiNeurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Via Conca 71, Ancona, 60020, Italy.
Alberto VerrottiDepartment of Pediatrics, University of L'Aquila, L'Aquila, Italy.
Gaetano ZaccaraUnit of Neurology, Department of Medicine, USL Centro Toscana Health Authority, Firenze, Italy.
Mauro SilvestriniNeurological Clinic, Department of Experimental and Clinical Medicine, Marche Polytechnic University, Via Conca 71, Ancona, 60020, Italy.
Marche Polytechnic University · ITAzienda Usl Toscana Centro · ITEisai (Italy) · ITUniversity of L'Aquila · ITUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the treatment of pediatric epilepsy, there is a critical demand for effective and safe therapeutic options to address patients' unmet clinical needs. Eslicarbazepine acetate is a novel once-daily antiepileptic drug and a third-generation single enantiomer member of the dibenzazepine family.

objectiveThe objective of this study was to evaluate the efficacy and safety of eslicarbazepine acetate as add-on treatment for focal-onset seizures in pediatric patients using meta-analytical techniques.

methodsRandomized, placebo-controlled, single- or double-blinded add-on trials of eslicarbazepine acetate in patients < 18 years of age with focal-onset seizures uncontrolled by concomitant stable antiepileptic drug regimens were identified through a systematic literature search. The assessed outcomes included the mean relative change and ≥ 50% reduction in the baseline seizure frequency, the incidence of treatment withdrawal, serious adverse events, and treatment-emergent adverse events. Risk ratio and weighted mean difference with 95% confidence intervals were estimated for dichotomous/continuous outcomes.

resultsTwo trials were included involving 386 participants (age range 2-18 years), 217 for eslicarbazepine acetate and 169 for placebo groups, respectively. At the dosage of 30 mg/kg/day, eslicarbazepine acetate-treated patients had a significantly greater reduction in baseline seizure frequency (weighted mean difference - 21.67, 95% confidence interval - 40.87 to - 2.46; p = 0.027) and 58 patients (44.6%) were seizure responders compared with 27 controls (29.7%) [risk ratio 1.48, 95% confidence interval 0.99-2.20; p = 0.055]. There were no differences in treatment withdrawal (risk ratio 1.24, 95% confidence interval 0.65-2.37; p = 0.513), serious adverse events (risk ratio 1.40, 95% confidence interval 0.69-2.86; p = 0.350), and treatment-emergent adverse events (risk ratio 1.07, 95% confidence interval 0.94-1.22; p = 0.313).

conclusionsAdjunctive eslicarbazepine acetate could be an effective well-tolerated option in children and adolescents with focal-onset seizures uncontrolled by one or more concomitant anti-epileptic drugs.

Indexed as

PediatricsAdolescentAnticonvulsantsChildChild, PreschoolDibenzazepinesEpilepsies, PartialHumansRandomized Controlled Trials as TopicAnticonvulsantsDibenzazepineseslicarbazepine acetate

Identifiers

PMID29508243
OpenAlexW2794104372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.